"What" Series

What is Berlin Patient?

18 April 2024
2 min read

The "Berlin Patient" refers to Timothy Ray Brown, an American man who was known as the first person to be cured of HIV/AIDS. Brown was living in Berlin, Germany, when he was diagnosed with both HIV and acute myeloid leukemia, a type of cancer affecting the blood and bone marrow.

In 2007 and 2008, Brown underwent two bone marrow transplants to treat his leukemia. His transplant donor had a rare genetic mutation known as CCR5-delta 32, which confers resistance to HIV by preventing the virus from entering human cells. This mutation occurs naturally in a small percentage of people of European descent.

After the transplants, not only did Brown's leukemia go into remission, but doctors also discovered that HIV could no longer be detected in his body. He stopped taking antiretroviral drugs, the standard treatment for HIV, and remained free of the virus until his death from a recurrence of cancer, unrelated to HIV, on September 29, 2020.

Timothy Ray Brown's case provided hope and valuable insights to the scientific community, indicating for the first time that a cure for HIV might be possible. However, bone marrow transplants are risky and not a practical or widely applicable method for curing HIV in most patients, largely due to the difficulty of finding suitable donors with the CCR5-delta 32 mutation and the high risk of transplant-related complications. Nonetheless, the "Berlin Patient" has become a symbol of the potential for medical advances in the fight against HIV/AIDS.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

An analysis of ASKC202's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
An analysis of ASKC202's R&D progress and its clinical results presented at the 2024 AACR Annual Meeting
18 April 2024
On April 5, 2024, the AACR reported the latest clinical trial results of ASKC202, illustrating its potential clinical benefits and setting the stage for further exploration.
Read →
What is Recurrence-free Survival?
"What" Series
2 min read
What is Recurrence-free Survival?
17 April 2024
Recurrence-free survival (RFS) is a clinical endpoint used in oncology to measure the effectiveness of cancer treatments.
Read →
What is the difference between EMA and HMA?
"What" Series
2 min read
What is the difference between EMA and HMA?
17 April 2024
EMA (European Medicines Agency) and HMA (Heads of Medicines Agencies) are two distinct organizations that play vital roles in the regulation of medicinal products, but their functions and scopes differ.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 17
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 17
17 April 2024
April 17th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.